



## Clinical trial results:

### A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or after Platinum-Based Therapy.

#### Summary

EudraCT number	2014-003655-66
Trial protocol	ES HU DK DE NL PL GB BE GR IT
Global end of trial date	26 July 2022

#### Results information

Result version number	v1 (current)
This version publication date	09 August 2023
First version publication date	09 August 2023

#### Trial information

##### Trial identification

Sponsor protocol code	I4T-MC-JVDC
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02426125
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 15679

Notes:

#### Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 July 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 July 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 July 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Romania: 10
Country: Number of subjects enrolled	Hungary: 13
Country: Number of subjects enrolled	United States: 35
Country: Number of subjects enrolled	Japan: 54
Country: Number of subjects enrolled	Ukraine: 8
Country: Number of subjects enrolled	United Kingdom: 42
Country: Number of subjects enrolled	Russian Federation: 30
Country: Number of subjects enrolled	Spain: 37
Country: Number of subjects enrolled	Greece: 26
Country: Number of subjects enrolled	Canada: 9
Country: Number of subjects enrolled	Korea, Republic of: 25
Country: Number of subjects enrolled	Netherlands: 35
Country: Number of subjects enrolled	Turkey: 28
Country: Number of subjects enrolled	Belgium: 7
Country: Number of subjects enrolled	Taiwan: 31
Country: Number of subjects enrolled	Denmark: 11
Country: Number of subjects enrolled	Poland: 8
Country: Number of subjects enrolled	Italy: 37
Country: Number of subjects enrolled	Mexico: 4

Country: Number of subjects enrolled	Israel: 18
Country: Number of subjects enrolled	Australia: 12
Country: Number of subjects enrolled	France: 34
Country: Number of subjects enrolled	Germany: 16
Worldwide total number of subjects	530
EEA total number of subjects	234

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	239
From 65 to 84 years	289
85 years and over	2

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Completers include participants who are confirmed to be alive at study completion.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Ramucirumab + Docetaxel
------------------	-------------------------

Arm description:

Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m<sup>2</sup>]) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Arm type	Experimental
Investigational medicinal product name	Ramucirumab
Investigational medicinal product code	
Other name	LY3009806
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received 10 mg/kg of Ramucirumab intravenously (IV) on day 1 of each 21-day cycle.

Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received 75 mg/m<sup>2</sup> of docetaxel Intravenously on day 1 of each 21-day cycle.

<b>Arm title</b>	Placebo + Docetaxel
------------------	---------------------

Arm description:

Placebo IV plus docetaxel (75 mg/m<sup>2</sup>) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Arm type	Placebo
Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received 75 mg/m<sup>2</sup> of docetaxel intravenously on day 1 of each 21-day cycle.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received matching placebo intravenously on day 1 of each 21-day cycle.

<b>Number of subjects in period 1</b>	Ramucirumab + Docetaxel	Placebo + Docetaxel
Started	263	267
Received at least one dose of study drug	258	265
Completed	46	39
Not completed	217	228
Adverse event, serious fatal	185	200
Consent withdrawn by subject	13	14
Randomized, But Never Treated	5	2
Lost to follow-up	14	12

## Baseline characteristics

### Reporting groups

Reporting group title	Ramucirumab + Docetaxel
-----------------------	-------------------------

Reporting group description:

Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m<sup>2</sup>]) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Reporting group title	Placebo + Docetaxel
-----------------------	---------------------

Reporting group description:

Placebo IV plus docetaxel (75 mg/m<sup>2</sup>) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Reporting group values	Ramucirumab + Docetaxel	Placebo + Docetaxel	Total
Number of subjects	263	267	530
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	64.6 ± 9.9	64.8 ± 9.2	-
Gender categorical Units: Subjects			
Female	50	52	102
Male	213	215	428
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	13	10	23
Not Hispanic or Latino	208	219	427
Unknown or Not Reported	42	38	80
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	1	0	1
Asian	54	61	115
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	3	2	5
White	203	204	407
More than one race	0	0	0
Unknown or Not Reported	2	0	2
Region of Enrollment Units: Subjects			
Romania	5	5	10
Hungary	5	8	13
United States	17	18	35
Japan	24	30	54
Ukraine	5	3	8
United Kingdom	18	24	42

Russia	18	12	30
Spain	22	15	37
Greece	13	13	26
Canada	4	5	9
South Korea	16	9	25
Netherlands	17	18	35
Turkey	11	17	28
Belgium	6	1	7
Taiwan	13	18	31
Denmark	5	6	11
Poland	4	4	8
Italy	23	14	37
Mexico	3	1	4
Israel	7	11	18
Australia	6	6	12
France	16	18	34
Germany	5	11	16

## End points

### End points reporting groups

Reporting group title	Ramucirumab + Docetaxel
Reporting group description: Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m <sup>2</sup> ]) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.	
Reporting group title	Placebo + Docetaxel
Reporting group description: Placebo IV plus docetaxel (75 mg/m <sup>2</sup> ) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.	

### Primary: Progression Free Survival (PFS)

End point title	Progression Free Survival (PFS)
End point description: PFS defined as time from first day of therapy to first evidence of disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions, with reference being the smallest sum on study and plus absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If participant does not have complete baseline disease assessment, then PFS time was censored at date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for participant. If participant is not known to have died or have objective progression as of data inclusion cutoff date for analysis, PFS time was censored at last adequate tumor assessment date. Analysis population description (APD): All randomized participants. Censored participants: Ramucirumab + Docetaxel = 51, Placebo + Docetaxel = 31.	
End point type	Primary
End point timeframe: Randomization to Radiological Disease Progression or Death from Any Cause (Up to 29.7 Months)	

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	267		
Units: Months				
median (confidence interval 95%)	4.07 (3.29 to 4.83)	2.76 (2.60 to 2.89)		

### Statistical analyses

Statistical analysis title	Progression Free Survival (PFS)
Comparison groups	Ramucirumab + Docetaxel v Placebo + Docetaxel

Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002 <sup>[1]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.696
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.573
upper limit	0.845

Notes:

[1] - Stratified

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description:	OS is the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data inclusion cutoff date for a particular analysis, OS was censored for that analysis at the last known alive date prior to the data inclusion cutoff date. APD: All randomized participants. Censored participants: Ramucirumab + Docetaxel = 78, Placebo + Docetaxel = 67.
End point type	Secondary
End point timeframe:	Randomization to Date of Death from Any Cause (Up to 31.1 Months)

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	267		
Units: Months				
median (confidence interval 95%)	9.40 (7.89 to 11.43)	7.85 (7.00 to 9.30)		

## Statistical analyses

Statistical analysis title	Overall Survival (OS)
Comparison groups	Ramucirumab + Docetaxel v Placebo + Docetaxel
Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2461 <sup>[2]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.887

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.724
upper limit	1.086

Notes:

[2] - Stratified

### Secondary: Percentage of Participants with an Objective Response Rate (ORR)

End point title	Percentage of Participants with an Objective Response Rate (ORR)
-----------------	--

End point description:

ORR is defined as the percentage of participants who achieve a best overall response of complete response (CR) + partial response (PR). ORR = CR + PR. CR is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 millimeter (mm). Tumor-marker results must have normalized. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Best overall response is classified based on the overall responses assessed by study investigators according to RECIST v1.1. APD: All randomized participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization to Disease Progression (Up to 29.7 Months)

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	267		
Units: percentage of participants				
number (confidence interval 95%)	25.9 (20.6 to 31.1)	13.9 (9.7 to 18.0)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with Disease Control Rate (DCR)

End point title	Percentage of Participants with Disease Control Rate (DCR)
-----------------	--

End point description:

DCR is percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1. Target lesions - CR: Disappearance of all lesions; any pathological lymph nodes must have reduction in short axis to <10 mm. PR: At least a 30% decrease in sum of diameters of lesions vs baseline sum. Progressive Disease (PD): At least a 20% increase in sum of diameters of lesions vs smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non target lesions - CR: Disappearance of all lesions and normalization of tumor marker levels; all lymph nodes must be non-pathological in size. Non-CR/Non-PD: Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels. PD: Unequivocal progression of existing lesions or the appearance of new lesion(s). APD: All randomized participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization to Disease Progression (Up to 29.7 Months)

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	267		
Units: percentage of participants				
number (confidence interval 95%)	65.4 (59.7 to 71.1)	55.1 (49.1 to 61.0)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Response (DoR)

End point title	Duration of Response (DoR)
End point description:	
Objective response was achieved if they had a best overall response of CR or PR. Target lesions- CR: Disappearance of all lesions;any pathological lymph nodes have reduction in short axis to <10 mm.PR: At least a 30% decrease in sum of diameters of lesions vs the baseline sum.PD: At least a 20% increase in sum of diameters of lesions vs smallest sum on study(the sum must also demonstrate an absolute increase of at least 5 mm); or appearance of new lesion(s). Non target lesions - CR: Disappearance of all lesions and normalization of tumour marker levels; all lymph nodes must be non-pathological in size. Non-CR/Non-PD: Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels. PD: Unequivocal progression of existing lesions or appearance of new lesion(s). If a participant was not known to have died or have radiographically documented PD as of data inclusion cutoff date, DOR was censored at the date of the last adequate tumor assessment. APD: All randomized participants	
End point type	Secondary
End point timeframe:	
Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up to 28.4 Months)	
Participants censored in Ramucirumab + Docetaxel = 12 and in Placebo + Docetaxel = 5.	

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	68	37		
Units: Months				
median (confidence interval 95%)	5.32 (3.94 to 6.87)	4.17 (3.29 to 5.55)		

## Statistical analyses

Statistical analysis title	Duration of Response (DoR)
Comparison groups	Ramucirumab + Docetaxel v Placebo + Docetaxel

Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.189
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.473
upper limit	1.158

### Secondary: Time to Deterioration in Quality of Life (QoL) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status/ QoL Scale

End point title	Time to Deterioration in Quality of Life (QoL) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) - Global Health Status/ QoL Scale
-----------------	--

#### End point description:

Time to sustained deterioration was defined as time from randomization to first worsening in QoL with no subsequent non-worsened assessment. Worsening in global health status/QoL was defined as a decrease of  $\geq 10$  points on a 100-point scale. If a participant did not report worsening, time to sustained deterioration was censored at date of last non-worsened assessment. Scores for global health status/QoL range from 0 to 100 with; higher scores representing better QoL. APD: All randomized participants. Censored participants: Ramucirumab + Docetaxel = 160, Placebo + Docetaxel = 173.

End point type	Secondary
End point timeframe:	
Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months)	

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	263	267		
Units: Months				
median (confidence interval 95%)	6.87 (4.24 to 8.90)	4.60 (3.52 to 5.55)		

### Statistical analyses

Statistical analysis title	Global health status/QoL
Comparison groups	Ramucirumab + Docetaxel v Placebo + Docetaxel

Number of subjects included in analysis	530
Analysis specification	Pre-specified
Analysis type	superiority <sup>[3]</sup>
P-value	= 0.357 <sup>[4]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.879
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.663
upper limit	1.167

Notes:

[3] - Global health status/QoL

[4] - Stratified

### Secondary: Change from Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score

End point title	Change from Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
-----------------	---

End point description:

The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Participants completed the 5-level (no problem, slight problem, moderate problem, severe problem, and inability or extreme problem), 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire concerning their current health state. A unique EQ-5D health state is defined by combining 1 level from each of the 5 dimensions. Scores range from 0 (death) to 1 (perfect health), but scores <0 are possible based on the algorithm. APD: All randomized participants with baseline and 30-day follow-up data.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months)

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	102		
Units: units on a scale				
arithmetic mean (standard deviation)	-0.10 (± 0.26)	-0.19 (± 0.26)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)

End point title	Change from Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)
-----------------	---

End point description:

The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. A unique

EQ-5D health state is defined by combining 1 level from each of the 5 dimensions. Participants indicated their current health status by marking on a VAS ranging from 100 (best imaginable health state) to 0 (worst imaginable health state).

APD: All randomized participants with baseline and 30-day follow-up data.

End point type	Secondary
End point timeframe:	
Randomization, 30 Days After Treatment Discontinuation (Up to 18 Months)	

End point values	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	86	105		
Units: millimeter (mm)				
arithmetic mean (standard deviation)	-7.87 ( $\pm$ 17.95)	-10.91 ( $\pm$ 16.77)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab

End point title	Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab <sup>[5]</sup>
-----------------	---

End point description:

Cmax of Ramucirumab at the end of ramucirumab infusion. APD: All randomized participants who had evaluable PK data.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 and Cycle 9, Day 1: Predose, Postdose

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is planned only for Ramucirumab arm in the baseline period per protocol.

End point values	Ramucirumab + Docetaxel			
Subject group type	Reporting group			
Number of subjects analysed	209 <sup>[6]</sup>			
Units: microgram/milliliter ( $\mu$ g/mL)				
geometric mean (geometric coefficient of variation)				
Cycle 1	199 ( $\pm$ 28)			
Cycle 9	265 ( $\pm$ 29)			

Notes:

[6] - Cycle 1: 209

Cycle 9: 22

## Statistical analyses

No statistical analyses for this end point

### Secondary: PK: Minimum Concentration (Cmin) of Ramucirumab

End point title	PK: Minimum Concentration (Cmin) of Ramucirumab <sup>[7]</sup>
-----------------	--

End point description:

Cmin of Ramucirumab following administration every 3 weeks. APD: All randomized participants who had evaluable PK data.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 of Cycle 2, 3, 5 and 9 (Predose and Postdose)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is planned only for Ramucirumab arm in the baseline period per protocol.

End point values	Ramucirumab + Docetaxel			
Subject group type	Reporting group			
Number of subjects analysed	188 <sup>[8]</sup>			
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Cycle 2	14.9 (± 64)			
Cycle 3	23.5 (± 63)			
Cycle 5	32.5 (± 70)			
Cycle 9	48.9 (± 56)			

Notes:

[8] - Cycle 2: 188; Cycle 3: 146; Cycle 5: 94; Cycle 9: 25

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants with Anti-Ramucirumab Antibodies

End point title	Number of Participants with Anti-Ramucirumab Antibodies
-----------------	---

End point description:

Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. APD: All randomized participants who received at least one dose of study drug at baseline and post-baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

29.7 Months

<b>End point values</b>	Ramucirumab + Docetaxel	Placebo + Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	199	213		
Units: participants	3	8		

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 64.7 Months

Adverse event reporting additional description:

All randomized participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

### Reporting groups

Reporting group title	Placebo+Docetaxel
-----------------------	-------------------

Reporting group description:

Placebo IV plus docetaxel (75 mg/m<sup>2</sup>) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Reporting group title	Ramucirumab + Docetaxel
-----------------------	-------------------------

Reporting group description:

Ramucirumab (10 mg/kg) IV plus docetaxel (75 mg/m<sup>2</sup>) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Serious adverse events	Placebo+Docetaxel	Ramucirumab + Docetaxel	
Total subjects affected by serious adverse events			
subjects affected / exposed	107 / 265 (40.38%)	111 / 258 (43.02%)	
number of deaths (all causes)	209	193	
number of deaths resulting from adverse events	5	8	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
tumour haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
arterial haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

aortic aneurysm			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
deep vein thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
embolism			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
haematoma			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hypertension			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
hypotension			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
venous occlusion			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
chest pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
death			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 2	1 / 2	
deaths causally related to treatment / all	1 / 2	1 / 2	
fatigue			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	5 / 258 (1.94%)	
occurrences causally related to treatment / all	2 / 2	3 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
general physical health deterioration			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
generalised oedema			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
malaise			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
mucosal inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
non-cardiac chest pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pyrexia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	9 / 265 (3.40%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	2 / 10	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
sudden death			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Reproductive system and breast disorders			
female genital tract fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed <sup>[1]</sup>	0 / 265 (0.00%)	1 / 49 (2.04%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
dyspnoea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	1 / 3	3 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
epistaxis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
hiccups			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
laryngeal inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

obstructive airways disorder alternative dictionary used: MedDRA 26.0 subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pleural effusion alternative dictionary used: MedDRA 26.0 subjects affected / exposed	7 / 265 (2.64%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 8	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumonitis alternative dictionary used: MedDRA 26.0 subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	1 / 1	0 / 1	
pneumothorax alternative dictionary used: MedDRA 26.0 subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
pulmonary embolism alternative dictionary used: MedDRA 26.0 subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
pulmonary hypertension alternative dictionary used: MedDRA 26.0 subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders delirium alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
mental status changes			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
device connection issue			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
blood creatinine increased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
neutrophil count decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	3 / 3	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
platelet count decreased			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
fall			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
infusion related reaction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
lower limb fracture			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
urostomy complication			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
arteriospasm coronary			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardiac arrest			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
cardiac failure			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardiac failure congestive alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
intracardiac thrombus alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
myocardial infarction alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
pericardial effusion alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
supraventricular tachycardia alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders basilar artery thrombosis alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
cerebrovascular accident			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
cerebral ischaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
dizziness			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
headache			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
presyncope			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
subarachnoid haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

syncope alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 265 (0.75%) 0 / 2 0 / 0	1 / 258 (0.39%) 0 / 1 0 / 0	
transient ischaemic attack alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 265 (0.38%) 1 / 1 0 / 0	0 / 258 (0.00%) 0 / 0 0 / 0	
Blood and lymphatic system disorders			
anaemia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	4 / 265 (1.51%) 1 / 4 0 / 0	0 / 258 (0.00%) 0 / 0 0 / 0	
blood loss anaemia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 265 (0.00%) 0 / 0 0 / 0	1 / 258 (0.39%) 0 / 1 0 / 0	
febrile neutropenia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	13 / 265 (4.91%) 11 / 14 0 / 0	17 / 258 (6.59%) 20 / 20 0 / 0	
leukopenia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 265 (0.75%) 3 / 3 0 / 0	0 / 258 (0.00%) 0 / 0 0 / 0	
neutropenia alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)	
occurrences causally related to treatment / all	2 / 2	5 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
pancytopenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
vertigo			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
abdominal pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
anal fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ascites			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
constipation			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
colitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
gastric haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
diarrhoea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	6 / 258 (2.33%)	
occurrences causally related to treatment / all	3 / 5	5 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
fistula of small intestine			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
enterovesical fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
enterocolitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
gastrointestinal ulcer			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
haemorrhoids			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ileal perforation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
intestinal ischaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
intestinal obstruction			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
intestinal perforation			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
large intestine perforation alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
oesophagitis alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
nausea alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	1 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
tooth disorder alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
rectal haemorrhage alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
small intestinal obstruction alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

small intestinal perforation alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 265 (0.00%) 0 / 0 0 / 0	1 / 258 (0.39%) 1 / 1 0 / 0	
stomatitis alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 265 (0.38%) 0 / 1 0 / 0	0 / 258 (0.00%) 0 / 0 0 / 0	
upper gastrointestinal haemorrhage alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 265 (0.38%) 1 / 1 0 / 0	0 / 258 (0.00%) 0 / 0 0 / 0	
vomiting alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 265 (0.75%) 2 / 2 0 / 0	3 / 258 (1.16%) 3 / 3 0 / 0	
Hepatobiliary disorders cholelithiasis alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 265 (0.00%) 0 / 0 0 / 0	1 / 258 (0.39%) 0 / 1 0 / 0	
Skin and subcutaneous tissue disorders dermatitis alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 265 (0.38%) 1 / 1 0 / 0	0 / 258 (0.00%) 0 / 0 0 / 0	
rash alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
acute kidney injury			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
haematuria			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	6 / 265 (2.26%)	4 / 258 (1.55%)	
occurrences causally related to treatment / all	1 / 6	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
hydronephrosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
renal failure			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	1 / 2	
ureteric stenosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
urinary tract obstruction			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
adrenal insufficiency			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
back pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
bone pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
fistula			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
myalgia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
muscular weakness			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
abdominal abscess			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
appendicitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
bronchitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
bacteraemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cellulitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cystitis			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
clostridium difficile colitis alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
diverticulitis alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
device related infection alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
gastroenteritis alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
gingivitis alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
kidney infection alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

lower respiratory tract infection alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences causally related to treatment / all	0 / 0	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		
infection alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)		
occurrences causally related to treatment / all	0 / 1	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		
neutropenic sepsis alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)		
occurrences causally related to treatment / all	0 / 0	1 / 1		
deaths causally related to treatment / all	0 / 0	1 / 1		
pneumonia alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	8 / 265 (3.02%)	5 / 258 (1.94%)		
occurrences causally related to treatment / all	3 / 8	3 / 5		
deaths causally related to treatment / all	1 / 3	0 / 0		
pneumonia aspiration alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)		
occurrences causally related to treatment / all	0 / 1	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 1		
pyelonephritis alternative dictionary used: MedDRA 26.0				
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)		
occurrences causally related to treatment / all	1 / 2	1 / 2		
deaths causally related to treatment / all	0 / 0	0 / 0		
respiratory tract infection alternative dictionary used: MedDRA 26.0				

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
sepsis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	7 / 258 (2.71%)	
occurrences causally related to treatment / all	5 / 5	3 / 7	
deaths causally related to treatment / all	0 / 0	1 / 4	
stoma site abscess			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
toxic shock syndrome			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
urosepsis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	5 / 265 (1.89%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	3 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
urinary tract infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	11 / 265 (4.15%)	10 / 258 (3.88%)	
occurrences causally related to treatment / all	2 / 15	2 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
dehydration			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
decreased appetite			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
diabetic metabolic decompensation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyperglycaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyperkalaemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyponatraemia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Placebo+Docetaxel	Ramucirumab + Docetaxel	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	251 / 265 (94.72%)	241 / 258 (93.41%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
neuroma			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
pyogenic granuloma			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
tumour necrosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
tumour pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	9 / 265 (3.40%)	1 / 258 (0.39%)	
occurrences (all)	13	1	
Vascular disorders			
cyanosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
deep vein thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	2 / 258 (0.78%)	
occurrences (all)	4	2	
embolism			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
flushing			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)
occurrences (all)	2	5
haematoma		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
hot flush		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)
occurrences (all)	2	2
hyperaemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
hypotension		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	8 / 265 (3.02%)	7 / 258 (2.71%)
occurrences (all)	8	10
hypertension		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	15 / 265 (5.66%)	34 / 258 (13.18%)
occurrences (all)	22	66
lymphocele		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
lymphoedema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)
occurrences (all)	2	1
pallor		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1

pelvic venous thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
phlebitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	3	
thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
venous thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
varicose vein			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
vasculitis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	6	
vena cava thrombosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
venous occlusion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
Surgical and medical procedures			

catheter placement alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
central venous catheterisation alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	1 / 258 (0.39%) 1	
endodontic procedure alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
nail operation alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
paracentesis alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
skin lesion removal alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
tooth extraction alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
General disorders and administration site conditions administration site extravasation alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)  administration site rash alternative dictionary used:	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	

MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
asthenia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	24 / 265 (9.06%)	29 / 258 (11.24%)
occurrences (all)	38	55
catheter site erythema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
chest discomfort		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	2
chest pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	4 / 265 (1.51%)	1 / 258 (0.39%)
occurrences (all)	4	1
chills		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	9 / 265 (3.40%)	6 / 258 (2.33%)
occurrences (all)	12	7
face oedema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)
occurrences (all)	1	3
extravasation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	2	0
fatigue		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	106 / 265 (40.00%)	98 / 258 (37.98%)
occurrences (all)	188	186
gait disturbance		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
generalised oedema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	2
general physical health deterioration		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)
occurrences (all)	2	1
hypothermia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
injection site reaction		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	5 / 258 (1.94%)
occurrences (all)	1	12
injection site extravasation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
infusion site reaction		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	2
infusion site extravasation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	4 / 258 (1.55%)
occurrences (all)	0	4

influenza like illness		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	7 / 265 (2.64%)	14 / 258 (5.43%)
occurrences (all)	7	15
localised oedema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	6 / 265 (2.26%)	1 / 258 (0.39%)
occurrences (all)	6	2
malaise		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	10 / 265 (3.77%)	18 / 258 (6.98%)
occurrences (all)	16	31
moaning		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
mucosal disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	2
mucosal inflammation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	4 / 265 (1.51%)	13 / 258 (5.04%)
occurrences (all)	7	26
nodule		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
non-cardiac chest pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	4 / 265 (1.51%)	4 / 258 (1.55%)
occurrences (all)	6	4
oedema peripheral		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	34 / 265 (12.83%)	38 / 258 (14.73%)
occurrences (all)	44	52
pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	8 / 265 (3.02%)	10 / 258 (3.88%)
occurrences (all)	8	14
oedema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)
occurrences (all)	1	3
peripheral swelling		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	3
pyrexia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	42 / 265 (15.85%)	44 / 258 (17.05%)
occurrences (all)	63	66
swelling		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2
swelling face		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2
tenderness		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
thirst decreased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0

<p>Immune system disorders</p> <p>allergy to arthropod sting</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 265 (0.00%)</p> <p>0</p> <p>1 / 258 (0.39%)</p> <p>1</p> <p>drug hypersensitivity</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 265 (0.38%)</p> <p>1</p> <p>2 / 258 (0.39%)</p> <p>2</p> <p>hypersensitivity</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>4 / 265 (1.51%)</p> <p>5</p> <p>2 / 258 (0.78%)</p> <p>2</p> <p>seasonal allergy</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 265 (0.38%)</p> <p>1</p> <p>1 / 258 (0.39%)</p> <p>1</p>			
<p>Reproductive system and breast disorders</p> <p>breast pain</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 265 (0.38%)</p> <p>1</p> <p>0 / 258 (0.00%)</p> <p>0</p> <p>female genital tract fistula</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed<sup>[2]</sup></p> <p>occurrences (all)</p> <p>0 / 265 (0.00%)</p> <p>0</p> <p>1 / 49 (2.04%)</p> <p>1</p> <p>genital haemorrhage</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 265 (0.38%)</p> <p>3</p> <p>0 / 258 (0.00%)</p> <p>0</p> <p>genital ulceration</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 265 (0.00%)</p> <p>0</p> <p>1 / 258 (0.39%)</p> <p>1</p> <p>gynaecomastia</p>			

alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[3]</sup>	1 / 214 (0.47%)	1 / 209 (0.48%)
occurrences (all)	1	1
intermenstrual bleeding		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[4]</sup>	0 / 265 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	2
oedema genital		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
pelvic discomfort		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
pelvic organ prolapse		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
pelvic pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	4 / 265 (1.51%)	5 / 258 (1.94%)
occurrences (all)	4	5
penile pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[5]</sup>	1 / 214 (0.47%)	0 / 258 (0.00%)
occurrences (all)	1	0
perineal pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
perineal ulceration		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
scrotal oedema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[6]</sup>	1 / 214 (0.47%)	3 / 209 (1.44%)
occurrences (all)	1	3
scrotal pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[7]</sup>	0 / 265 (0.00%)	3 / 209 (1.44%)
occurrences (all)	0	3
scrotal swelling		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[8]</sup>	1 / 214 (0.47%)	0 / 258 (0.00%)
occurrences (all)	1	0
testicular oedema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[9]</sup>	1 / 214 (0.47%)	0 / 258 (0.00%)
occurrences (all)	1	0
testicular pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[10]</sup>	1 / 214 (0.47%)	1 / 209 (0.48%)
occurrences (all)	1	1
vaginal haemorrhage		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[11]</sup>	1 / 51 (1.96%)	1 / 49 (2.04%)
occurrences (all)	1	1
vulvovaginal pruritus		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[12]</sup>	0 / 265 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	1
vulval haemorrhage		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[13]</sup>	0 / 265 (0.00%)	1 / 49 (2.04%)
occurrences (all)	0	1

Respiratory, thoracic and mediastinal disorders			
aphonia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
bronchospasm			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
chylothorax			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
cough			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	26 / 265 (9.81%)	21 / 258 (8.14%)	
occurrences (all)	29	30	
dyspnoea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	34 / 265 (12.83%)	32 / 258 (12.40%)	
occurrences (all)	40	50	
dysphonia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	8 / 258 (3.10%)	
occurrences (all)	3	10	
dry throat			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
dyspnoea exertional			

alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)
occurrences (all)	3	1
epistaxis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	14 / 265 (5.28%)	39 / 258 (15.12%)
occurrences (all)	16	56
haemoptysis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
hiccups		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	8 / 265 (3.02%)	14 / 258 (5.43%)
occurrences (all)	8	21
hypoxia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
laryngeal inflammation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
laryngeal pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
lung opacity		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
nasal dryness		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2
oropharyngeal pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	5 / 265 (1.89%)	10 / 258 (3.88%)
occurrences (all)	5	11
pleural effusion		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)
occurrences (all)	2	4
pneumonitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)
occurrences (all)	2	4
productive cough		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)
occurrences (all)	2	5
pulmonary embolism		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)
occurrences (all)	2	2
pulmonary fibrosis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
pulmonary haemorrhage		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
rhinorrhoea		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	6 / 265 (2.26%)	7 / 258 (2.71%)
occurrences (all)	6	8

respiratory tract congestion alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
rhinitis allergic alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	3 / 265 (1.13%) 3	3 / 258 (1.16%) 3	
sinus congestion alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
tracheal inflammation alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
upper respiratory tract congestion alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
upper respiratory tract inflammation alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
upper-airway cough syndrome alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	2 / 265 (0.75%) 3	0 / 258 (0.00%) 0	
wheezing alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	2 / 265 (0.75%) 2	1 / 258 (0.39%) 1	
Psychiatric disorders			

anxiety		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	8 / 265 (3.02%)	6 / 258 (2.33%)
occurrences (all)	10	6
confusional state		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)
occurrences (all)	4	1
depressive symptom		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
depression		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	4 / 265 (1.51%)	3 / 258 (1.16%)
occurrences (all)	4	3
delirium		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
disorientation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
emotional distress		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
euphoric mood		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
insomnia		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	10 / 265 (3.77%)	23 / 258 (8.91%)	
occurrences (all)	11	25	
irritability			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)	
occurrences (all)	0	2	
restlessness			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
sleep disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
sleep talking			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
Product issues			
device occlusion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
cholelithiasis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
hepatic failure			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
hepatic function abnormal			
alternative dictionary used: MedDRA 26.0			

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p>	<p>0 / 258 (0.00%)</p> <p>0</p>	
<p>hepatic pain</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 265 (0.00%)</p> <p>0</p>	<p>1 / 258 (0.39%)</p> <p>1</p>	
<p>jaundice</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p>	<p>1 / 258 (0.39%)</p> <p>1</p>	
Investigations			
<p>activated partial thromboplastin time prolonged</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 265 (0.00%)</p> <p>0</p>	<p>1 / 258 (0.39%)</p> <p>1</p>	
<p>alanine aminotransferase increased</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>8 / 265 (3.02%)</p> <p>8</p>	<p>9 / 258 (3.49%)</p> <p>9</p>	
<p>aspartate aminotransferase increased</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>9 / 265 (3.40%)</p> <p>9</p>	<p>11 / 258 (4.26%)</p> <p>12</p>	
<p>blood alkaline phosphatase</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p>	<p>0 / 258 (0.00%)</p> <p>0</p>	
<p>blood alkaline phosphatase increased</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>11 / 265 (4.15%)</p> <p>14</p>	<p>4 / 258 (1.55%)</p> <p>4</p>	
<p>blood bilirubin increased</p> <p>alternative dictionary used: MedDRA 26.0</p>			

subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	6
blood calcium decreased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
blood creatine increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
blood creatinine increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	21 / 265 (7.92%)	8 / 258 (3.10%)
occurrences (all)	31	8
blood lactate dehydrogenase increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	2
blood pressure decreased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
blood pressure increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	3 / 258 (1.16%)
occurrences (all)	7	9
blood thyroid stimulating hormone increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
blood urea increased		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)
occurrences (all)	2	0
blood uric acid increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
body temperature increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
carbon dioxide decreased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	3
clostridium test positive		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
creatinine renal clearance decreased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	2	0
electrocardiogram st segment depression		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
gamma-glutamyltransferase increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	10 / 265 (3.77%)	1 / 258 (0.39%)
occurrences (all)	13	1
heart rate increased		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
international normalised ratio increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
lymphocyte count decreased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	8 / 265 (3.02%)	5 / 258 (1.94%)
occurrences (all)	26	15
lymphocyte count increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	2	0
neutrophil count decreased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	29 / 265 (10.94%)	29 / 258 (11.24%)
occurrences (all)	71	93
neutrophil count increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
platelet count decreased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	6 / 265 (2.26%)	21 / 258 (8.14%)
occurrences (all)	9	56
platelet count increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
protein total increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1

protein urine		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
protein urine present		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	4
prothrombin time prolonged		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
total lung capacity decreased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
troponin t increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
weight increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)
occurrences (all)	3	1
weight decreased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	21 / 265 (7.92%)	23 / 258 (8.91%)
occurrences (all)	28	26
white blood cells urine positive		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
white blood cells urine		
alternative dictionary used: MedDRA 26.0		

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 265 (0.00%)</p> <p>0</p>	<p>1 / 258 (0.39%)</p> <p>1</p>	
<p>white blood cell count increased</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p>	<p>0 / 258 (0.00%)</p> <p>0</p>	
<p>white blood cell count decreased</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>21 / 265 (7.92%)</p> <p>54</p>	<p>19 / 258 (7.36%)</p> <p>77</p>	
<p>Injury, poisoning and procedural complications</p> <p>contusion</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p>	<p>2 / 258 (0.78%)</p> <p>2</p>	
<p>eschar</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p>	<p>0 / 258 (0.00%)</p> <p>0</p>	
<p>fall</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p>	<p>3 / 258 (1.16%)</p> <p>3</p>	
<p>fracture</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 265 (0.00%)</p> <p>0</p>	<p>1 / 258 (0.39%)</p> <p>1</p>	
<p>head injury</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 265 (0.00%)</p> <p>0</p>	<p>1 / 258 (0.39%)</p> <p>1</p>	
<p>infusion related reaction</p> <p>alternative dictionary used: MedDRA 26.0</p>			

subjects affected / exposed	6 / 265 (2.26%)	7 / 258 (2.71%)
occurrences (all)	6	9
jaw fracture		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
joint injury		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
limb injury		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
nail injury		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
pelvic fracture		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
penis injury		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed <sup>[14]</sup>	1 / 214 (0.47%)	0 / 258 (0.00%)
occurrences (all)	1	0
periorbital haematoma		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
post procedural haemorrhage		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)
occurrences (all)	0	3

procedural pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
procedural nausea			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
rib fracture			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
skin abrasion			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)	
occurrences (all)	2	1	
spinal fracture			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
thermal burn			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
stoma site pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
urinary tract stoma complication			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
vascular access complication			
alternative dictionary used: MedDRA 26.0			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>wound complication</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>wound</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p> <p>0 / 265 (0.00%)</p> <p>0</p> <p>0 / 265 (0.00%)</p> <p>0</p>	<p>0 / 258 (0.00%)</p> <p>0</p> <p>1 / 258 (0.39%)</p> <p>1</p> <p>1 / 258 (0.39%)</p> <p>1</p>	
<p>Congenital, familial and genetic disorders</p> <p>haemophilia</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 265 (0.00%)</p> <p>0</p>	<p>1 / 258 (0.39%)</p> <p>1</p>	
<p>Cardiac disorders</p> <p>angina pectoris</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>atrial fibrillation</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>atrioventricular block first degree</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>arrhythmia</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>cardiac failure</p> <p>alternative dictionary used: MedDRA 26.0</p>	<p>0 / 265 (0.00%)</p> <p>0</p> <p>1 / 265 (0.38%)</p> <p>1</p> <p>2 / 265 (0.75%)</p> <p>2</p> <p>1 / 265 (0.38%)</p> <p>1</p>	<p>1 / 258 (0.39%)</p> <p>1</p> <p>1 / 258 (0.39%)</p> <p>1</p> <p>0 / 258 (0.00%)</p> <p>0</p> <p>0 / 258 (0.00%)</p> <p>0</p>	

subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	2
cardiovascular disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
bradycardia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
left ventricular dysfunction		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
palpitations		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)
occurrences (all)	2	3
pericardial effusion		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
sinus bradycardia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
sinus tachycardia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	4 / 265 (1.51%)	0 / 258 (0.00%)
occurrences (all)	4	0
right atrial enlargement		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0

tachyarrhythmia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
tachycardia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	2 / 265 (0.75%) 2	3 / 258 (1.16%) 3	
Nervous system disorders ageusia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	3 / 265 (1.13%) 3	0 / 258 (0.00%) 0	
amnesia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	1 / 258 (0.39%) 1	
ataxia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
clonus alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 2	0 / 258 (0.00%) 0	
depressed level of consciousness alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 3	0 / 258 (0.00%) 0	
drooling alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
dizziness postural alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
dizziness		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	9 / 265 (3.40%)	7 / 258 (2.71%)
occurrences (all)	9	8
disturbance in attention		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	2
dysgeusia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	18 / 265 (6.79%)	28 / 258 (10.85%)
occurrences (all)	19	41
dysarthria		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	2
dysaesthesia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
head titubation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	2	0
headache		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	14 / 265 (5.28%)	19 / 258 (7.36%)
occurrences (all)	15	27
hypoesthesia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	2 / 258 (0.78%)
occurrences (all)	3	2

hypotonia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
lethargy		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)
occurrences (all)	1	3
memory impairment		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2
nervous system disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
neuralgia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
neuropathy peripheral		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	13 / 265 (4.91%)	7 / 258 (2.71%)
occurrences (all)	16	9
neurotoxicity		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	3 / 258 (1.16%)
occurrences (all)	2	3
paraesthesia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	14 / 265 (5.28%)	5 / 258 (1.94%)
occurrences (all)	15	7
peripheral sensory neuropathy		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	22 / 265 (8.30%)	18 / 258 (6.98%)
occurrences (all)	31	23
peroneal nerve palsy		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
polyneuropathy		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
peripheral motor neuropathy		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)
occurrences (all)	2	1
presyncope		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
radiculopathy		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
sciatica		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
syncope		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)
occurrences (all)	2	0
taste disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2

<p>somnolence</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p>	<p>2 / 258 (0.78%)</p> <p>2</p>	
<p>tremor</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 265 (1.13%)</p> <p>4</p>	<p>2 / 258 (0.78%)</p> <p>3</p>	
<p>Blood and lymphatic system disorders</p> <p>anaemia</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>blood loss anaemia</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>febrile neutropenia</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>leukocytosis</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>leukopenia</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>lymph node pain</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>lymphopenia</p> <p>alternative dictionary used: MedDRA 26.0</p>	<p>76 / 265 (28.68%)</p> <p>140</p> <p>0 / 265 (0.00%)</p> <p>0</p> <p>5 / 265 (1.89%)</p> <p>5</p> <p>3 / 265 (1.13%)</p> <p>3</p> <p>5 / 265 (1.89%)</p> <p>9</p> <p>1 / 265 (0.38%)</p> <p>1</p>	<p>50 / 258 (19.38%)</p> <p>87</p> <p>1 / 258 (0.39%)</p> <p>1</p> <p>9 / 258 (3.49%)</p> <p>9</p> <p>1 / 258 (0.39%)</p> <p>1</p> <p>8 / 258 (3.10%)</p> <p>25</p> <p>0 / 258 (0.00%)</p> <p>0</p>	

subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)	
occurrences (all)	2	7	
neutropenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	14 / 265 (5.28%)	18 / 258 (6.98%)	
occurrences (all)	14	36	
thrombocytopenia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	6 / 258 (2.33%)	
occurrences (all)	3	13	
thrombocytosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
ear discomfort			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
ear canal stenosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
hypoacusis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	2	0	
middle ear inflammation			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
otorrhoea			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
tinnitus			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
vestibular disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
vertigo			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	0 / 258 (0.00%)	
occurrences (all)	4	0	
Eye disorders			
dry eye			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	2 / 265 (0.75%)	3 / 258 (1.16%)	
occurrences (all)	2	3	
eczema eyelids			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
eye discharge			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
eye disorder			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
eye pain			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	4
eye pruritus		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
eyelid function disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
eyelid oedema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
eyelid ptosis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
glaucoma		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
lacrimation increased		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	12 / 265 (4.53%)	24 / 258 (9.30%)
occurrences (all)	12	28
ocular discomfort		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
photopsia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1

retinal vascular disorder alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 2	0 / 258 (0.00%) 0	
vitreous haemorrhage alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
vitreous detachment alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
visual impairment alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
vision blurred alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	3 / 258 (1.16%) 3	
Gastrointestinal disorders abdominal discomfort alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	2 / 258 (0.78%) 2	
abdominal distension alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	5 / 265 (1.89%) 5	7 / 258 (2.71%) 7	
abdominal wall disorder alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 2	0 / 258 (0.00%) 0	
abdominal pain lower alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
abdominal pain upper		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	10 / 265 (3.77%)	12 / 258 (4.65%)
occurrences (all)	10	15
abdominal pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	17 / 265 (6.42%)	20 / 258 (7.75%)
occurrences (all)	22	26
anal fistula		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
anal haemorrhage		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
anal incontinence		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
anal inflammation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
angular cheilitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
ascites		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	7 / 258 (2.71%)
occurrences (all)	1	8

cheilitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
colitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
constipation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	45 / 265 (16.98%)	35 / 258 (13.57%)
occurrences (all)	58	46
diarrhoea		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	56 / 265 (21.13%)	81 / 258 (31.40%)
occurrences (all)	81	131
dysphagia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	6 / 258 (2.33%)
occurrences (all)	2	6
dyspepsia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	7 / 265 (2.64%)	9 / 258 (3.49%)
occurrences (all)	7	10
dyschezia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
dry mouth		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	5 / 265 (1.89%)	11 / 258 (4.26%)
occurrences (all)	5	13
ectopic gastric mucosa		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
eructation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
epigastric discomfort		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
enterocolitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
flatulence		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
faeces discoloured		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
gastrointestinal obstruction		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
gastrointestinal motility disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
gastritis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1

gastric polyps		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
food poisoning		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
gastrooesophageal reflux disease		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	4 / 265 (1.51%)	3 / 258 (1.16%)
occurrences (all)	4	8
gingival atrophy		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
gingival bleeding		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)
occurrences (all)	0	3
haematochezia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	3 / 258 (1.16%)
occurrences (all)	2	3
glossitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
gingival pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	2
hiatus hernia		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
hyperchlorhydria		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
haemorrhoidal haemorrhage		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
haemorrhoids		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	8 / 258 (3.10%)
occurrences (all)	2	9
ileus		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2
intestinal haemorrhage		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
intra-abdominal haematoma		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
large intestinal haemorrhage		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
lip blister		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1

mouth ulceration		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
melaena		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	2	1
lip dry		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
mucous stools		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
odynophagia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)
occurrences (all)	2	0
nausea		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	55 / 265 (20.75%)	71 / 258 (27.52%)
occurrences (all)	82	102
obstruction gastric		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	5
oral disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
oral hyperaesthesia		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
oral pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)
occurrences (all)	2	1
periodontal disease		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)
occurrences (all)	2	2
proctalgia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2
proctitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
rectal haemorrhage		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)
occurrences (all)	3	1
rectal prolapse		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
rectal tenesmus		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2
stomatitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	30 / 265 (11.32%)	66 / 258 (25.58%)
occurrences (all)	36	117

toothache alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	4 / 265 (1.51%) 4	1 / 258 (0.39%) 1	
upper gastrointestinal haemorrhage alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
vomiting alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	40 / 265 (15.09%) 56	41 / 258 (15.89%) 62	
Skin and subcutaneous tissue disorders			
acne alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
alopecia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	94 / 265 (35.47%) 115	66 / 258 (25.58%) 79	
dermatitis alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
decubitus ulcer alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
dermatitis acneiform alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
dry skin alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	6 / 265 (2.26%)	11 / 258 (4.26%)
occurrences (all)	6	12
drug eruption		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
eczema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	4
epidermolysis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
erythema		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	6 / 258 (2.33%)
occurrences (all)	3	7
erythema multiforme		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	0 / 258 (0.00%)
occurrences (all)	3	0
hyperhidrosis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)
occurrences (all)	2	2
nail bed disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
nail bed inflammation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1

nail discolouration		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	15 / 265 (5.66%)	7 / 258 (2.71%)
occurrences (all)	15	7
nail disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	3 / 258 (1.16%)
occurrences (all)	3	3
nail dystrophy		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
nail toxicity		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	4
night sweats		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)
occurrences (all)	2	2
nail ridging		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	6 / 258 (2.33%)
occurrences (all)	3	7
onychalgia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	5
onycholysis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	5 / 258 (1.94%)
occurrences (all)	3	7
onychomadesis		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	5 / 265 (1.89%)	8 / 258 (3.10%)
occurrences (all)	5	10
onychoclasia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
pain of skin		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)
occurrences (all)	0	3
palmar-plantar erythrodysaesthesia syndrome		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	6 / 265 (2.26%)	19 / 258 (7.36%)
occurrences (all)	15	28
photosensitivity reaction		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	2
pruritus		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	12 / 265 (4.53%)	10 / 258 (3.88%)
occurrences (all)	17	11
rash		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	15 / 265 (5.66%)	11 / 258 (4.26%)
occurrences (all)	18	14
rash erythematous		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
rash maculo-papular		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	5 / 265 (1.89%)	0 / 258 (0.00%)
occurrences (all)	5	0

skin burning sensation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
skin discolouration		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
skin disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	2
skin exfoliation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
skin fissures		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
skin hyperpigmentation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	2 / 258 (0.78%)
occurrences (all)	2	2
skin lesion		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
skin ulcer		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	3
urticaria		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	4 / 265 (1.51%)	5 / 258 (1.94%)	
occurrences (all)	4	5	
xeroderma			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
Renal and urinary disorders			
acute kidney injury			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	5 / 258 (1.94%)	
occurrences (all)	0	5	
anuria			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
bladder pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
chromaturia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	
chronic kidney disease			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
cystitis noninfective			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
cystitis interstitial			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
dysuria		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	4 / 265 (1.51%)	3 / 258 (1.16%)
occurrences (all)	4	3
haematuria		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	19 / 265 (7.17%)	30 / 258 (11.63%)
occurrences (all)	20	48
hydronephrosis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
hydroureter		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
micturition urgency		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	2
nocturia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
pollakiuria		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	4 / 265 (1.51%)	3 / 258 (1.16%)
occurrences (all)	4	3
polyuria		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1

proteinuria		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	16 / 265 (6.04%)	33 / 258 (12.79%)
occurrences (all)	28	60
renal failure		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)
occurrences (all)	2	1
renal impairment		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2
renal pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
urinary hesitation		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
urethral haemorrhage		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
urinary fistula		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
urinary tract pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)
occurrences (all)	2	0
urinary tract obstruction		
alternative dictionary used: MedDRA 26.0		

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>urinary retention</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>urinary incontinence</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>urine odour abnormal</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p> <p>5 / 265 (1.89%)</p> <p>6</p> <p>6 / 265 (2.26%)</p> <p>6</p> <p>2 / 265 (0.75%)</p> <p>2</p>	<p>2 / 258 (0.78%)</p> <p>2</p> <p>1 / 258 (0.39%)</p> <p>1</p> <p>1 / 258 (0.39%)</p> <p>1</p> <p>1 / 258 (0.39%)</p> <p>1</p>	
<p>Endocrine disorders</p> <p>adrenal insufficiency</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>hypothyroidism</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 265 (0.38%)</p> <p>1</p> <p>1 / 265 (0.38%)</p> <p>1</p>	<p>0 / 258 (0.00%)</p> <p>0</p> <p>2 / 258 (0.78%)</p> <p>3</p>	
<p>Musculoskeletal and connective tissue disorders</p> <p>arthralgia</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>arthritis</p> <p>alternative dictionary used: MedDRA 26.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>back pain</p> <p>alternative dictionary used: MedDRA 26.0</p>	<p>26 / 265 (9.81%)</p> <p>34</p> <p>0 / 265 (0.00%)</p> <p>0</p>	<p>30 / 258 (11.63%)</p> <p>39</p> <p>1 / 258 (0.39%)</p> <p>1</p>	

subjects affected / exposed	21 / 265 (7.92%)	29 / 258 (11.24%)
occurrences (all)	26	36
bone pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	17 / 265 (6.42%)	15 / 258 (5.81%)
occurrences (all)	19	15
flank pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	5 / 265 (1.89%)	3 / 258 (1.16%)
occurrences (all)	6	3
groin pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	7 / 265 (2.64%)	4 / 258 (1.55%)
occurrences (all)	7	6
intervertebral disc disorder		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
intervertebral disc protrusion		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
inguinal mass		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
joint effusion		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
joint swelling		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1

limb discomfort			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
muscle fatigue			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
muscle spasms			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	2 / 258 (0.78%)	
occurrences (all)	4	4	
muscle twitching			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
muscular weakness			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	6 / 265 (2.26%)	5 / 258 (1.94%)	
occurrences (all)	7	6	
musculoskeletal chest pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	3 / 265 (1.13%)	4 / 258 (1.55%)	
occurrences (all)	3	4	
musculoskeletal pain			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	4 / 265 (1.51%)	1 / 258 (0.39%)	
occurrences (all)	4	1	
myalgia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	23 / 265 (8.68%)	24 / 258 (9.30%)	
occurrences (all)	30	39	
myofascitis			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
neck mass		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
neck pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	5 / 265 (1.89%)	3 / 258 (1.16%)
occurrences (all)	7	3
osteoarthritis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
osteonecrosis of jaw		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
pain in extremity		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	16 / 265 (6.04%)	12 / 258 (4.65%)
occurrences (all)	22	15
pain in jaw		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
polymyalgia rheumatica		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
pubic pain		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1

sacral pain alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	1 / 258 (0.39%) 1	
spinal pain alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
Infections and infestations abscess intestinal alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
anal abscess alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
bacteraemia alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
bacteriuria alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	1 / 265 (0.38%) 1	0 / 258 (0.00%) 0	
covid-19 alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	0 / 265 (0.00%) 0	1 / 258 (0.39%) 1	
cellulitis alternative dictionary used: MedDRA 26.0 subjects affected / exposed occurrences (all)	2 / 265 (0.75%) 2	2 / 258 (0.78%) 3	
breast cellulitis alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
bronchitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	4 / 258 (1.55%)
occurrences (all)	3	4
conjunctivitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	5 / 258 (1.94%)
occurrences (all)	1	6
cystitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2
device related infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	2
dacryocystitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	2
enterovirus infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
eye infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	0 / 258 (0.00%)
occurrences (all)	2	0
gastroenteritis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0

furuncle		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	2
fungus infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
gingivitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	4 / 258 (1.55%)
occurrences (all)	2	4
helicobacter infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
herpes dermatitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
herpes virus infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	2	0
herpes zoster		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	2 / 258 (0.78%)
occurrences (all)	1	2
influenza		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)
occurrences (all)	1	3
infective glossitis		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
kidney infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
lower respiratory tract infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
nail bed infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	3
nail infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	5 / 258 (1.94%)
occurrences (all)	1	7
mucosal infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
nasopharyngitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	5 / 258 (1.94%)
occurrences (all)	3	5
onychomycosis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	2	0

oral candidiasis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	5 / 258 (1.94%)
occurrences (all)	3	5
oral fungal infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
oral herpes		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
paronychia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	3
parotitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
perineal abscess		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	2	0
perineal infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	2
postoperative wound infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
peritonitis bacterial		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
pharyngitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	2
pneumonia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	3 / 265 (1.13%)	1 / 258 (0.39%)
occurrences (all)	5	1
post procedural infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
pyelonephritis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	2
pyelonephritis acute		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
respiratory tract infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
respiratory tract infection viral		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
rhinitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	3 / 258 (1.16%)
occurrences (all)	1	5

sepsis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
sinusitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	2 / 265 (0.75%)	1 / 258 (0.39%)
occurrences (all)	2	1
skin infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
spinal cord infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
tooth infection		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	3 / 258 (1.16%)
occurrences (all)	0	3
tooth abscess		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	2 / 258 (0.78%)
occurrences (all)	0	2
tonsillitis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
tinea pedis		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
tracheitis		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
upper respiratory tract infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	9 / 265 (3.40%)	5 / 258 (1.94%)	
occurrences (all)	9	5	
urethritis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
urinary tract infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	34 / 265 (12.83%)	31 / 258 (12.02%)	
occurrences (all)	39	38	
viral upper respiratory tract infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
viral infection			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
acidosis			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)	
occurrences (all)	1	0	
cachexia			
alternative dictionary used: MedDRA 26.0			
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)	
occurrences (all)	0	1	
dehydration			
alternative dictionary used: MedDRA 26.0			

subjects affected / exposed	5 / 265 (1.89%)	8 / 258 (3.10%)
occurrences (all)	5	8
decreased appetite		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	64 / 265 (24.15%)	82 / 258 (31.78%)
occurrences (all)	82	128
fluid retention		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	0 / 265 (0.00%)	1 / 258 (0.39%)
occurrences (all)	0	1
gout		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	1	1
hypercalcaemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	12 / 265 (4.53%)	6 / 258 (2.33%)
occurrences (all)	15	11
hyperglycaemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	13 / 265 (4.91%)	8 / 258 (3.10%)
occurrences (all)	15	12
hyperkalaemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	7 / 265 (2.64%)	12 / 258 (4.65%)
occurrences (all)	12	26
hypophosphataemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	7 / 265 (2.64%)	6 / 258 (2.33%)
occurrences (all)	8	10
hypophagia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0

hyponatraemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	10 / 265 (3.77%)	7 / 258 (2.71%)
occurrences (all)	11	10
hypomagnesaemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	5 / 265 (1.89%)	4 / 258 (1.55%)
occurrences (all)	7	4
hypokalaemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	5 / 265 (1.89%)	3 / 258 (1.16%)
occurrences (all)	7	3
hypocalcaemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	4 / 265 (1.51%)	2 / 258 (0.78%)
occurrences (all)	6	2
hypoalbuminaemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	26 / 265 (9.81%)	17 / 258 (6.59%)
occurrences (all)	32	25
hyperuricaemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	15 / 265 (5.66%)	10 / 258 (3.88%)
occurrences (all)	17	11
hypernatraemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	0 / 258 (0.00%)
occurrences (all)	1	0
hypermagnesaemia		
alternative dictionary used: MedDRA 26.0		
subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)
occurrences (all)	2	1
vitamin d deficiency		
alternative dictionary used: MedDRA 26.0		

subjects affected / exposed	1 / 265 (0.38%)	1 / 258 (0.39%)	
occurrences (all)	1	1	

#### Notes:

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[12] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[13] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

[14] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported